Last Updated:
10 Mar 2026, 03:29:56 PM (IST)
J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARM BSE: JBCHEPHARM
NSE
2,117.40
45.80 (2.21%)
Prev Close
2071.6
Open Price
2084.8
Volume
706,890
Today Low / High
2077.2 / 2125
52 WK Low / High
1385.75 / 2125
Range
2,012 - 2,223
BSE
2,119.25
49.35 (2.38%)
Prev Close
2069.9
Open Price
2070.9
Volume
5,386
Today Low / High
2070.9 / 2125.4
52 WK Low / High
1303 / 2125.4
Range
2,013 - 2,225
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2117.4 (target range: 2,012 - 2,223), reflecting a change of 45.8 (2.21085%). On the BSE, it is listed at 2119.25 (target range: 2,013 - 2,225), showing a change of 49.35 (2.38417%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
27 Feb
2,089.40
-1.72%
26 Feb
2,090.90
-0.45%
25 Feb
2,089.00
-0.15%
24 Feb
2,032.30
1.87%
23 Feb
2,019.90
1.34%
20 Feb
1,985.00
0.77%
19 Feb
1,984.10
0.42%
J. B. Chemicals & Pharmaceuticals Limited Graph
J. B. Chemicals & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for J. B. Chemicals & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,117.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,119.25 | 2,140.44 | 1,926.40 - 2,354.49 |
| 2,161.64 | 1,729.31 - 2,593.96 | ||
| 2,182.83 | 1,527.98 - 2,837.68 | ||
| Bearish Scenario | 2,119.25 | 2,098.06 | 1,888.25 - 2,307.86 |
| 2,076.87 | 1,661.49 - 2,492.24 | ||
| 2,055.67 | 1,438.97 - 2,672.37 |
Overview of J. B. Chemicals & Pharmaceuticals Limited
ISIN
INE572A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
218,405
Market Cap
329,466,735,410
Last Dividend
19.7
Official Website
IPO Date
2002-07-01
DCF Diff
-1,920.53
DCF
3,994
Financial Ratios Every Investor Needs
Stock Dividend of JBCHEPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-11 | February 11, 26 | 12.7 | 12.7 | 2026-02-11 | 2026-02-25 | |
| 2025-07-30 | July 30, 25 | 7 | 7 | 2025-07-30 | 2025-08-13 | |
| 2025-02-07 | February 07, 25 | 8.5 | 8.5 | 2025-02-08 | 2025-02-21 | |
| 2024-08-14 | August 14, 24 | 6.75 | 6.75 | 2024-08-14 | 2024-09-20 | |
| 2024-02-16 | February 16, 24 | 5.5 | 5.5 | 2024-02-16 | 2024-03-07 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,917.99 Cr | 1,316.55 Cr | 2,601.44 Cr | 0.6640 | 44.84 Cr | 36.25 Cr | 1,913.83 Cr | 659.58 Cr | 42.45 | 1,031.84 Cr | 0.1683 |
| 2024-03-31 | 3,484.18 Cr | 2,121.75 Cr | 1,345.88 Cr | 0.3863 | 30.56 Cr | 603.43 Cr | 754.16 Cr | 552.63 Cr | 35.66 | 933.48 Cr | 0.1586 |
| 2023-03-31 | 3,116.51 Cr | 2,015.49 Cr | 1,114.44 Cr | 0.3576 | 31.93 Cr | 547.04 Cr | 584.51 Cr | 409.84 Cr | 26.50 | 704.37 Cr | 0.1315 |
| 2022-03-31 | 2,424.24 Cr | 863.37 Cr | 1,560.87 Cr | 0.6439 | 29.11 Cr | 441.28 Cr | 460.48 Cr | 385.36 Cr | 24.93 | 581.53 Cr | 0.1590 |
| 2021-03-31 | 2,005.85 Cr | 717.44 Cr | 1,288.41 Cr | 0.6423 | 23.53 Cr | 341.95 Cr | 455.67 Cr | 447.96 Cr | 28.98 | 672.26 Cr | 0.2233 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 129.45 Cr | 4,273.78 Cr | 840.46 Cr | 3,433.3200 Cr | 27.89 Cr | -101.56 Cr | 528.95 Cr | 656.64 Cr | 10.32 Cr | 1.90 Cr | 27.98 Cr | 632.3300 Cr |
| 2024-03-31 | 88.22 Cr | 3,994.13 Cr | 1,070.80 Cr | 2,923.3300 Cr | 377.66 Cr | 289.44 Cr | 502.51 Cr | 634.88 Cr | 12.99 Cr | 1.70 Cr | 29.09 Cr | 868.2261 Cr |
| 2023-03-31 | 76.93 Cr | 3,553.87 Cr | 1,073.52 Cr | 2,480.3500 Cr | 572.45 Cr | 495.52 Cr | 430.49 Cr | 576.42 Cr | 118.25 Cr | 2.49 Cr | 28.09 Cr | 554.4500 Cr |
| 2022-03-31 | 56.54 Cr | 2,607.40 Cr | 468.79 Cr | 2,134.1230 Cr | 54.56 Cr | -1.99 Cr | 409.96 Cr | 566.82 Cr | 116.47 Cr | 3.17 Cr | 12.72 Cr | 383.7156 Cr |
| 2021-03-31 | 28.69 Cr | 2,238.12 Cr | 424.69 Cr | 1,809.7248 Cr | 44.99 Cr | 16.30 Cr | 347.45 Cr | 569.66 Cr | 108.56 Cr | 4.93 Cr | -651.88 Cr | 345.2737 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 902.4500 Cr | -295.8900 Cr | -579.6800 Cr | 804.8600 Cr | 26.8700 Cr | 115.0900 Cr | -97.5900 Cr | 659.5800 Cr | -343.9200 Cr | -237.0400 Cr | -26.4400 Cr |
| 2024-03-31 | 800.6117 Cr | -407.9074 Cr | -341.2720 Cr | 539.2447 Cr | 11.0507 Cr | 88.2151 Cr | -126.1128 Cr | 552.6278 Cr | -191.5957 Cr | -156.9875 Cr | -72.0300 Cr |
| 2023-03-31 | 625.6100 Cr | -961.7900 Cr | 356.5400 Cr | -139.3400 Cr | 20.3900 Cr | 76.9300 Cr | -764.9500 Cr | 555.2300 Cr | 523.1596 Cr | -127.5926 Cr | -20.5200 Cr |
| 2022-03-31 | 170.1345 Cr | 2.3199 Cr | -138.3851 Cr | -536.6547 Cr | 34.0703 Cr | 56.5441 Cr | -706.7892 Cr | 504.9020 Cr | -0.3273 Cr | -127.5628 Cr | -62.5143 Cr |
| 2021-03-31 | 314.7849 Cr | -230.6758 Cr | -87.4228 Cr | 267.0119 Cr | -3.2782 Cr | 22.4737 Cr | -47.7730 Cr | 596.8854 Cr | 0.3223 Cr | -73.2403 Cr | -70.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,064.72 Cr | 566.20 Cr | 498.52 Cr | 0.4682 | 250.47 Cr | 197.89 Cr | 12.63 | 314.10 Cr | 0.1859 |
| 2025-09-30 | 1,084.90 Cr | 345.49 Cr | 739.41 Cr | 0.6815 | 265.16 Cr | 207.82 Cr | 13.29 | 324.94 Cr | 0.1916 |
| 2025-06-30 | 1,093.94 Cr | 584.09 Cr | 509.85 Cr | 0.4661 | 258.17 Cr | 202.38 Cr | 12.97 | 315.42 Cr | 0.1850 |
| 2025-03-31 | 949.48 Cr | 321.64 Cr | 627.84 Cr | 0.6612 | 1,233.03 Cr | 145.69 Cr | 9.36 | 222.76 Cr | 0.1534 |
| 2024-12-31 | 963.49 Cr | 316.74 Cr | 646.75 Cr | 0.6713 | 212.57 Cr | 162.49 Cr | 10.46 | 262.51 Cr | 0.1686 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 93.78 Cr | 807.60 Cr | 901.38 Cr | 938.32 Cr | 576.58 Cr | 2,555.13 Cr | 678.66 Cr | 4,712.40 Cr | 906.66 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 450.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,433.32 Cr |
| 2025-03-31 | 129.45 Cr | 335.00 Cr | 446.56 Cr | 815.38 Cr | 528.95 Cr | 1,922.74 Cr | 656.64 Cr | 4,273.78 Cr | 840.46 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 416.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,212.23 Cr |
| 2024-09-30 | 97.46 Cr | 319.40 Cr | 416.86 Cr | 817.14 Cr | 543.67 Cr | 1,913.30 Cr | 641.67 Cr | 4,029.41 Cr | 817.18 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 202.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 145.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 162.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 174.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 176.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-09-18 | September 18, 23 | 2:1 |
| 2005-04-05 | April 05, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Head of Representative Office - Tashkent & Uzbekistan
Alisher Djabbarov
Gender: Not Specified
Year Born:
Vice President of Finance & Accounts
Bhagwat Singh Deora
Gender: male
Year Born: 1982
Vice President of Legal
Himanshu Ranvah
Gender: male
Year Born: 1985
President of Operations
Kunal Khanna
Gender: male
Year Born: 1980
Chief Financial Officer
Narayan Saraf
Gender: male
Year Born: 1980
Chief Executive Officer & Whole-Time Director
Nikhil Ashokkumar Chopra
Gender: male
Year Born: 1973
Executive Vice President of Operations of Daman
Parmeshwar Bang
Gender: male
Year Born: 1968
President of Global Business
Pradeep Kumar Singh
Gender: male
Year Born: 1964
Vice President of Secretarial & Company Secretary and Compliance Officer
Sandeep Anil Phadnis
Gender: male
Year Born: 1968
Vice President of Human Resources & Administration
Sridhar Bharadwaj
Gender: male
Year Born: 1967
Vice President of Information & Technology
Suresh Bhise
Gender: male
Year Born: 1966
Assistant Vice President Human Resource
Suresh Amin
Gender: Not Specified
Year Born:
FAQs about J. B. Chemicals & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Nikhil Ashokkumar Chopra.
What is the current market price of the stock?
The current price is ₹2,052.40.
What is the 52-week price range?
The range is ₹1385.75-2114.7.
What is the market capitalization of the company?
The market capitalization is ₹32,946.67 crores.
What is the dividend yield?
The dividend yield is 0.96%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 42.65.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of J. B. Chemicals & Pharmaceuticals Limited (ISIN: INE572A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹32,946.67 crores and an average daily volume of 218,405 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹19.7.